fashion -WSS

fashion

author：Wikipedia 2025-10-01 01:50:00 - browse：79946

Senate Health, Education, Labor, and Pensions Committee Chairman Bernie Sanders looks at Moderna CEO Stephane Bancel as he testifies. Sitting next to Sanders, ranking member Sen. Bill Cassidy looks down – policy coverage from STAT — Committee Ranking Republican Bill Cassidy (La.) and Chairman Bernie Sanders (I-Vt.) Chip Somodevilla/Getty Images

WASHINGTON – The Senate health committee on Thursday passed a package of bills aimed at speeding generic drug competition and reining in drug middlemen business practices. But they failed to pass an ambitious reform to the pharmacy benefit manager sector, despite strong bipartisan support for it.

Chairman Bernie Sanders (I-Vt.) is pursuing the drug pricing reforms at the behest of Senate Majority Leader Chuck Schumer (D-N.Y.), who wants to hold a floor vote on an even bigger package of health bills later this year. The markup came just a day after the same panel held a major hearing on PBM and drugmakers’ role in high insulin prices.

It’s not clear when the Senate would take up that package, and while the package is bipartisan, it’s not clear whether it has enough support among House Republicans to pass in that chamber. There are a few, tamer PBM bills that the House Energy and Commerce Committee is expected to mark up May 17, but there is no indication that Senate and House lawmakers are coordinating on PBM legislation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： How state and local governments are sidelining science

focus

WSS

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

FDA reorg will put new emphasis on investigations, sources say

Biotech lab space demand falls sharply

Ventyx halts psoriasis drug development after lackluster trial results

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Carbon Health diabetes program, a test of data

leisure time

fashion

focus

In age of alternative facts, a scholarly course on calling out crap

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

At least 13 dead in Texas as scorching temps continue

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Hepatitis C has a cure — but many Americans still lack access to it

EpiPen alternative approval delay highlights citizen petition issue

Peter Hotez and the public health issue of online harassment

Drug for rare kidney disease narrowly misses mark in clinical trial

Sports medicine is finally prioritizing gender equality

Publishing genetic code of viruses could cause disaster

focus

Publishing genetic code of viruses could cause disaster

Senate HELP committee spars over health care workforce policies

Thermo Fisher plant for manufacturing gene therapies to expand

Biotech lab space demand falls sharply

Second xenotransplant done with gene

First transplant of an entire human eye performed

focus

knowledge

focus

hotspot